Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.6%

Nov 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	5/26/2021 2:17:01 PM
	Read Replies (1) of 3557

Interesting issue, barrons.com. REGN has a deal with the US government worth up to $2.6B to supply Covid19 antibodies. They total payout depends supplying 1m doses by by June 30th. Currently there's emergency approval for doses at 2400 mg. REGN reported a Phase III trial indicating similar efficacy at 1200mg. If the FDA approves the lower dose, then the deadline could be met. On May 6th, the CEO said he expected action from the FDA "sometime in the next several weeks." An analyst is quoted as saying a timely announcement could make a difference of almost a $1B to Q2 sales and might shift the stock price by 5 or 10%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next